Canned-Food Producer Del Monte Foods Files for Bankruptcy
The firm entered a restructuring support agreement with lenders and started voluntary Chapter 11 proceedings to implement its terms, it said in a statement. It secured a commitment for $912.5 million in debtor-in-possession financing, inclusive of $165 million in new funding, from certain existing lenders.
A filing with the United States Bankruptcy Court for the District of New Jersey states that the company has both liabilities and assets estimated between $1 billion and $10 billion.
The development ends a challenging year for the borrower that saw its parent company Del Monte Pacific Ltd. in June elect to skip a payment to the unit's lenders as part of a lawsuit settlement tied to a controversial debt restructuring.
Del Monte Foods said in its statement that the restructuring support agreement contemplates the company undertaking a going-concern sale process for all or substantially all of its assets. Financing along with cash from ongoing operations is expected to provide sufficient liquidity during the sale process and fund ongoing operations, as it intends to keep serving customers, according to the statement.
Del Monte Foods executed a debt overhaul last year, which became the subject of a lawsuit by left-behind lenders who said the company defaulted on a $725 million financing agreement when it shifted the assets away from the reach of lenders.
The strategy — known in industry parlance as a drop-down transaction — allowed Del Monte Foods to raise fresh liquidity by borrowing against the transferred assets. The deal also prioritized participating lenders via debt swaps and created different payment priorities, Bloomberg reported.
More stories like this are available on bloomberg.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Apple CEO Tim Cook on Apple's 18 Years journey to 3 Billion iPhones
Apple has now shipped three billion iPhones since the launch of the original iPhone 18 years ago, in 2007. During Apple's third-quarter earnings call, CEO Tim Cook revealed that the company shipped its three billionth iPhone during the quarter. Apple also reported $94 billion in revenue, with iPhone sales contributing $44.6 billion, nearly half of its total quarterly revenue. While it took nine years to reach the first billion iPhones sold in 2016, the company hit two billion by 2021, just five years later. The jump from two to three billion took only four years, signaling growing global demand despite market saturation concerns. iPhone sales jumped 13% year-over-year in the quarter ending June 2025, with analysts suggesting tariff concerns may have driven purchases. Bloomberg reporter Mark Gurman noted that consumers likely bought iPhones fearing future price increases due to President Trump's proposed tariffs, which already cost Apple $800 million last quarter and are projected to reach $1.1 billion next quarter. While company executive Eddy Cue recently admitted consumers "may not need an iPhone 10 years from now," CEO Tim Cook pushed back against concerns about advanced AI replacing the iPhone, stating "it's difficult to see a world" without iPhones during Q3 2025 earnings call. Apple's slow rollout of AI features has left analysts mixed on its competitive edge, even as the company attempts to diversify through its Vision Pro headset and expanded AI initiatives.
Mint
4 hours ago
- Mint
Novo Nordisk Shares Post Worst Ever Week as Optimism Wanes
(Bloomberg) -- Just six weeks ago, things seemed to be getting better for Novo Nordisk A/S. Investors were optimistic, and the Danish drugmaker was briefly Europe's most valuable public company again. Now, the stock has posted its worst week on record. The shares have plunged 32% this week after the maker of Ozempic and Wegovy cut its forecasts for the year and named a company insider as its new chief executive officer. The stock was also hit on Friday after US President Donald Trump demanded that pharmaceutical companies lower American drug prices. That's taken Novo's market capitalization to the equivalent of $213 billion — below companies including Nestle SA and AstraZeneca Plc. The Danish firm dropped out of Europe's top 10 most valuable stocks on Friday morning, before regaining the final slot in that list later in the day. 'We've long been calling Novo a 'show me' story,' Barclays Plc analyst Emily Field wrote in a note this week. But with Novo having a hard time competing with cheaper, copycat versions of its medicines, and a new drug pipeline that lags behind rivals, 'we struggle to see what will get investors to return' to the story, Field wrote, downgrading the stock to equal-weight from overweight. Novo's warning on Tuesday followed a tumultuous year that's seen the shares plunge 70% from last summer's record high. Issues have included disappointing clinical trial results for experimental drugs, mounting competition from Eli Lilly & Co. and the ouster of its former CEO. Novo named company veteran Maziar Mike Doustdar as its new leader this week, 'but this won't be an easy fix,' warned Barclays' Field. Novo is due to report second-quarter results on Wednesday. One area that has been a particular headache for Novo is competition from cheaper copycat options for US patients. Compounding pharmacies are allowed to make and sell cheaper copies of a medicine when brand-name drugs are in short supply, and although they lost this permission this year, it remains an issue. Novo blamed its guidance cut on unrepentant compounders and broader competition. Many investors and analysts were caught off guard by the warning, with the mood in June being mainly one of optimism that a turnaround was starting. On Monday, nearly two-thirds of analysts tracked by Bloomberg rated the stock a buy or equivalent. But caution is starting to seep in, with less than half keeping their buy recommendations as of Friday's market close. Read: Novo Nordisk Shares Are Now Recovering from Peak Pessimism 'We got our call on Novo wrong,' said Rajesh Kumar, an analyst at HSBC. 'Our assumption that with FDA's ban on compounding, Novo might regain market share has not played out,' he wrote in a note on Thursday, cutting the stock to hold from buy. Still, one investor sees similarities between Novo's current situation and another upheaval for the drugmaker in 2016 when it was better known as the world's biggest maker of insulin. Will James, a fund manager at Guinness Global Investors, notes that back then, the company had its competitive position questioned. The guidance was cut and the CEO replaced. 'The share price fell and then recovered aggressively as Novo refocused its innovation and commercial efforts,' James said in an email. 'It is now undoubtedly a bigger job for the new CEO with a sizeable mountain to climb to regain and grow market share and rebuild trust with investors.' --With assistance from Michael Msika, Sagarika Jaisinghani and Blaise Robinson. More stories like this are available on
NDTV
6 hours ago
- NDTV
'Donald Trump's Tariff To Have 'Negligibe Impact... 0.2% GDP Hit': Sources
New Delhi: The 25 per cent tariff announced by Donald Trump on Indian exports to the United States will have a 'negligible' impact on the economy, government sources told NDTV Friday afternoon. The GDP loss is not likely to exceed 0.2 per cent, sources said, echoing what an India-based economist told Bloomberg (article behind paywall) - that GDP would likely slow by 0.3 per cent only. A 0.2 per cent hit to GDP - Rs 330.68 lakh crore nominal in FY 2024/25 - is 'manageable'. Sources also stressed the government will not bow to American pressure to open price-sensitive agriculture and dairy markets, or allow the import of beef or 'non-veg milk', i.e., milk from cows fed animal-based products like bonemeal. These may offend religious sentiments, sources said. The government will also act to 'secure national interest' and remains committed to the welfare of farmers, entrepreneurs, and MSMEs (Micro, Small and Medium Enterprises), sources said. Farmers merited a separate mention. NDTV was told the government would not compromise their interests, and would not, therefore, allow the import of GM, or genetically modified, crops. The 25 per cent tariff was announced against the backdrop of stalled trade deal talks. Those talks stalled because the US wanted its farmers and dairy producers to be able to sell in India. India has repeatedly said it cannot open these markets. Agriculture and allied sectors contribute less than 20 per cent to India's GDP. However, nearly half the country's 144 crore population is either directly or indirectly employed in those sectors. NDTV Explains | How Trump's 25% Tariff Will Impact Indian Markets That makes it a massive vote bank no government can risk upsetting, a fact underlined by the ruling BJP being forced into rolling back three farm laws in 2021 after violent protests. A stand-off over this topic reportedly angered Trump. Hours before the 25 per cent was announced, he told US reporters, "India has been a good friend... but has charged basically more tariffs than almost any other country... you just can't do that." Overall, the US is India's largest trading partner and has been so for four years now. Bilateral trade in 2024/25 was valued at $132 billion. In the last fiscal exports to the US rose by 11.6 per cent to $86.51 billion as against $77.52 billion in the preceding year. Imports, meanwhile, were up to $45.33 billion as against $42.2 billion in 2023-24. Meanwhile, sources also said negotiations for the bilateral trade deal with the US - which has been in the works since November last year - are on track and 'moving in the right direction'. A review of the 25 per cent tariff, and talks to reduce this, will be taken up after that deal is finalised, sources said. Last week NDTV was told India is close to finalising an interim deal. An announcement is expected by September or October. There was hope such this could be worked out before the 25 per cent tariff takes effect - on August 7 - but now appears unlikely.
